Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.

摘要: Told from the viewpoint of rheumatologists, this review tells story hydroxychloroquine and its swift ascent to become a household name as therapeutic strategy against novel SARS-CoV-2 virus. This describes history, mechanisms, pharmacokinetics, applications, safety profile an immunomodulatory antiviral agent. It also summarizes major studies that launched assessed use COVID-19 infection. More recent literature calls into question long-held dogma endolysosomal alkalinization is primary mode action hydroxychloroquine. Ongoing uncertainty about multiple potential mechanisms contributing effect in rheumatic viral disease led natural avenue for exploration treatment COVID-19. Taken whole, does not support utilizing treat or prevent infection is, at least part, due wide variability pharmacokinetics between patients difficulty achieving adequate target tissue concentrations without encountering unacceptable toxicities. Hydroxychloroquine continues be routinely prescribed, well-tolerated, effective, low-cost disease. Its versatility has frequent repurposing other conditions, most recently investigative Despite overall negative findings, intense study enhanced our understanding how operates autoimmune beyond.